Ping Wang1, Dawei Yang2, Honglian Zhang3, Xuyu Wei4, Tianle Ma4, Zule Cheng1, Qunying Hong2, Jie Hu2, Hanjing Zhuo2, Yuanlin Song2, Chunping Jia3, Fengxiang Jing3, Qinghui Jin3, Chunxue Bai2, Hongju Mao5, Jianlong Zhao3. 1. State Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Science, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China. 2. Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. 3. State Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Science, Shanghai, China. 4. Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 5. State Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Science, Shanghai, China. Electronic address: hjmao@mail.sim.ac.cn.
Abstract
INTRODUCTION: The objective of the study was to develop a panel of microRNAs (miRNAs) as highly sensitive and specific biomarkers for lung cancer early detection. MATERIALS AND METHODS: The study contained 2 phases: first, preliminary marker selection based on previous reports on the serum of 24 early stage lung cancer patients and 24 healthy control subjects by TaqMan probe-based real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR); and second, validation of miRNA markers on 94 early stage lung cancer, 48 stage III to IV lung cancer, and 111 healthy control serum samples. RESULTS: A total of 3 miRNAs (miR-125a-5p, miR-25, and miR-126) were selected for further analysis in this study. The combination of the 3 miRNAs could produce 0.936 area under the receiver operating characteristic curve value in distinguishing early stage lung cancer patients from control subjects with 87.5% sensitivity and 87.5% specificity, respectively. The diagnostic value of the miRNA panel in an independent set of lung cancer patients confirmed the sensitivity and specificity. CONCLUSION: The results demonstrated that the panel of miRNA biomarkers had the potential for the early detection of lung cancer.
INTRODUCTION: The objective of the study was to develop a panel of microRNAs (miRNAs) as highly sensitive and specific biomarkers for lung cancer early detection. MATERIALS AND METHODS: The study contained 2 phases: first, preliminary marker selection based on previous reports on the serum of 24 early stage lung cancerpatients and 24 healthy control subjects by TaqMan probe-based real-time reverse transcription-quantitative polymerase chain reaction (RT-qPCR); and second, validation of miRNA markers on 94 early stage lung cancer, 48 stage III to IV lung cancer, and 111 healthy control serum samples. RESULTS: A total of 3 miRNAs (miR-125a-5p, miR-25, and miR-126) were selected for further analysis in this study. The combination of the 3 miRNAs could produce 0.936 area under the receiver operating characteristic curve value in distinguishing early stage lung cancerpatients from control subjects with 87.5% sensitivity and 87.5% specificity, respectively. The diagnostic value of the miRNA panel in an independent set of lung cancerpatients confirmed the sensitivity and specificity. CONCLUSION: The results demonstrated that the panel of miRNA biomarkers had the potential for the early detection of lung cancer.
Authors: Jane V Carter; Henry L Roberts; Jianmin Pan; Jonathan D Rice; James F Burton; Norman J Galbraith; Maurice R Eichenberger; Jeffery Jorden; Peter Deveaux; Russell Farmer; Anna Williford; Ziad Kanaan; Shesh N Rai; Susan Galandiuk Journal: Ann Surg Date: 2016-10 Impact factor: 12.969
Authors: Ahmed Abdelrahman; Caterina Negroni; Felix Sahm; Claire L Adams; Tadeja Urbanic-Purkart; Michael Khalil; Raffaellla Vergura; Cristina Morelli; Clemens Oliver Hanemann Journal: J Neurooncol Date: 2022-09-08 Impact factor: 4.506
Authors: Martina Faraldi; Laura Gerosa; Marta Gomarasca; Veronica Sansoni; Silvia Perego; Ewa Ziemann; Giuseppe Banfi; Giovanni Lombardi Journal: Diagnostics (Basel) Date: 2021-04-30